Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of enlicitide decanoate coadministered with rosuvastatin in adults with hyperlipidemia
2025-521495-54-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in hyperlipidemia comparing Enlicitide decanoate + rosuvastatin with Placebo + rosuvastatin (2 arms). Primary endpoint: Mean percent change from baseline in low-density lipoprotein cholesterol at Week 8. Started Dec 2025; status: completed.
02
Drugs
enlicitiderosuvastatin
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on 2025-521495-54-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521495-54-00.